A Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer (Alliance A022004)
- Citation:
- J Clin Oncol vol 41 (suppl 16) TPS3641
- Meeting Instance:
- ASCO 2023
- Year:
- 2023
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Pfizer, Eli Lily;
- Grants:
- U10CA180821, U10CA180882; U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG);
- Corr. Author:
- Authors:
- Rona Yaeger Qian Shi Amylou Dueck Elie Dib Syed Kazmi Olatunji Alese Smitha Krishnamurthi Andrew Nixon Ardaman Shergill Eileen O'Reilly Jeffrey Meyerhardt
- Networks:
- LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC010, LAPS-NY016, LAPS-TX011, MCRC, OH027
- Study
- Alliance-A022004
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2/3
- Keywords: